MARKET

JUNS

JUNS

JUPITER NEUROSCIENCES, INC.
NASDAQ
2.510
-0.160
-5.99%
After Hours: 2.620 +0.11 +4.38% 17:38 09/28 EDT
OPEN
2.670
PREV CLOSE
2.670
HIGH
2.670
LOW
2.400
VOLUME
53.00K
TURNOVER
--
52 WEEK HIGH
137.96
52 WEEK LOW
2.400
MARKET CAP
3.31M
P/E (TTM)
-0.1352
1D
5D
1M
3M
1Y
5Y
1D
Jupiter Neurosciences files to sell 132,867 shares of common stock for holders
TipRanks · 3d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at JUNS last week (0914-0918)?
Weekly Report · 09/21 09:14
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/15 21:06
Weekly Report: what happened at JUNS last week (0907-0911)?
Weekly Report · 09/14 09:15
Weekly Report: what happened at JUNS last week (0831-0904)?
Weekly Report · 09/07 09:14
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/31 21:06
More
About JUNS
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.

Webull offers Jupiter Neurosciences Inc stock information, including NASDAQ: JUNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JUNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JUNS stock methods without spending real money on the virtual paper trading platform.